Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial

Detalhes bibliográficos
Autor(a) principal: Mello,Marcelo Feijo
Data de Publicação: 2008
Outros Autores: Costa,Mariana Cadrobbi Pupo, Schoedl,Aline Ferri, Fiks,Jose Paulo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462008000400011
Resumo: OBJECTIVE: Post traumatic stress disorder is frequent in the general population (7.8%-lifetime-USA). The selective serotonin reuptake inhibitors are the first choice of treatment but result in low remission rates. This study aims to evaluate the effect of aripiprazole monotherapy for the treatment of post traumatic stress disorder. METHOD: Thirty-two patients diagnosed with post traumatic stress disorder were included in a 16-week open label trial of aripiprazole. They were evaluated at baseline, week 8, and 16 with the Clinician-Administered PTSD Scale, Beck Depression Inventory, Beck Anxiety Inventory, Medical Outcome Study Short Form 36, and Social Adjustment Scale. Statistical analysis were performed with an intention-to-treat approach and last observation carried forward. A general linear model for repeated measures comparing the factor with 3 continuous measures from baseline, 8 and 16 weeks was used. A between-subject factor was included RESULTS: Nine patients discontinued the treatment. The mean aripiprazole dose was 9.6 (± 4.3) mg/day. The mean scores at baseline and endpoint for all measures were: Clinician-Administered PTSD Scale - 82.7 (± 23.1) and 51.4 (± 31.4) (F = 11.247, p = 0.001); Beck Anxiety Inventory - 31.7 (± 13.4) and 25.4 (± 18.2) (F = 8.931, p = 0.011); Social Adjustment Scale - 2.4 (± 0.45) and 2.27 (± 0.57) (F = 8.633, p = 0.012); Medical Outcome Study Short Form 36 - 76.6 (± 14.11) and 94.01 (± 25.06) (F = 10.127 p = 0.007); and Beck Depression Inventory - 26.06 (± 11.6) and 21.35 (± 12.6) (F = 1.580, p = 0.042). In all measurements, the differences were statistically significant. CONCLUSIONS: Patients achieved a good response to treatment with aripiprazole, but placebo-controlled studies are needed for more accurate results.
id ABP-1_be8c661514dfb4b654c930e601111cf9
oai_identifier_str oai:scielo:S1516-44462008000400011
network_acronym_str ABP-1
network_name_str Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
repository_id_str
spelling Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trialAripiprazolePatientsStress disorderspost-traumaticTreatmentRandomized controlled trialOBJECTIVE: Post traumatic stress disorder is frequent in the general population (7.8%-lifetime-USA). The selective serotonin reuptake inhibitors are the first choice of treatment but result in low remission rates. This study aims to evaluate the effect of aripiprazole monotherapy for the treatment of post traumatic stress disorder. METHOD: Thirty-two patients diagnosed with post traumatic stress disorder were included in a 16-week open label trial of aripiprazole. They were evaluated at baseline, week 8, and 16 with the Clinician-Administered PTSD Scale, Beck Depression Inventory, Beck Anxiety Inventory, Medical Outcome Study Short Form 36, and Social Adjustment Scale. Statistical analysis were performed with an intention-to-treat approach and last observation carried forward. A general linear model for repeated measures comparing the factor with 3 continuous measures from baseline, 8 and 16 weeks was used. A between-subject factor was included RESULTS: Nine patients discontinued the treatment. The mean aripiprazole dose was 9.6 (± 4.3) mg/day. The mean scores at baseline and endpoint for all measures were: Clinician-Administered PTSD Scale - 82.7 (± 23.1) and 51.4 (± 31.4) (F = 11.247, p = 0.001); Beck Anxiety Inventory - 31.7 (± 13.4) and 25.4 (± 18.2) (F = 8.931, p = 0.011); Social Adjustment Scale - 2.4 (± 0.45) and 2.27 (± 0.57) (F = 8.633, p = 0.012); Medical Outcome Study Short Form 36 - 76.6 (± 14.11) and 94.01 (± 25.06) (F = 10.127 p = 0.007); and Beck Depression Inventory - 26.06 (± 11.6) and 21.35 (± 12.6) (F = 1.580, p = 0.042). In all measurements, the differences were statistically significant. CONCLUSIONS: Patients achieved a good response to treatment with aripiprazole, but placebo-controlled studies are needed for more accurate results.Associação Brasileira de Psiquiatria2008-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462008000400011Brazilian Journal of Psychiatry v.30 n.4 2008reponame:Brazilian Journal of Psychiatry (São Paulo. 1999. Online)instname:Associação Brasileira de Psiquiatria (ABP)instacron:ABP10.1590/S1516-44462008000400011info:eu-repo/semantics/openAccessMello,Marcelo FeijoCosta,Mariana Cadrobbi PupoSchoedl,Aline FerriFiks,Jose Pauloeng2008-12-17T00:00:00Zoai:scielo:S1516-44462008000400011Revistahttp://www.bjp.org.br/ahead_of_print.asphttps://old.scielo.br/oai/scielo-oai.php||rbp@abpbrasil.org.br1809-452X1516-4446opendoar:2008-12-17T00:00Brazilian Journal of Psychiatry (São Paulo. 1999. Online) - Associação Brasileira de Psiquiatria (ABP)false
dc.title.none.fl_str_mv Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial
title Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial
spellingShingle Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial
Mello,Marcelo Feijo
Aripiprazole
Patients
Stress disorders
post-traumatic
Treatment
Randomized controlled trial
title_short Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial
title_full Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial
title_fullStr Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial
title_full_unstemmed Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial
title_sort Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial
author Mello,Marcelo Feijo
author_facet Mello,Marcelo Feijo
Costa,Mariana Cadrobbi Pupo
Schoedl,Aline Ferri
Fiks,Jose Paulo
author_role author
author2 Costa,Mariana Cadrobbi Pupo
Schoedl,Aline Ferri
Fiks,Jose Paulo
author2_role author
author
author
dc.contributor.author.fl_str_mv Mello,Marcelo Feijo
Costa,Mariana Cadrobbi Pupo
Schoedl,Aline Ferri
Fiks,Jose Paulo
dc.subject.por.fl_str_mv Aripiprazole
Patients
Stress disorders
post-traumatic
Treatment
Randomized controlled trial
topic Aripiprazole
Patients
Stress disorders
post-traumatic
Treatment
Randomized controlled trial
description OBJECTIVE: Post traumatic stress disorder is frequent in the general population (7.8%-lifetime-USA). The selective serotonin reuptake inhibitors are the first choice of treatment but result in low remission rates. This study aims to evaluate the effect of aripiprazole monotherapy for the treatment of post traumatic stress disorder. METHOD: Thirty-two patients diagnosed with post traumatic stress disorder were included in a 16-week open label trial of aripiprazole. They were evaluated at baseline, week 8, and 16 with the Clinician-Administered PTSD Scale, Beck Depression Inventory, Beck Anxiety Inventory, Medical Outcome Study Short Form 36, and Social Adjustment Scale. Statistical analysis were performed with an intention-to-treat approach and last observation carried forward. A general linear model for repeated measures comparing the factor with 3 continuous measures from baseline, 8 and 16 weeks was used. A between-subject factor was included RESULTS: Nine patients discontinued the treatment. The mean aripiprazole dose was 9.6 (± 4.3) mg/day. The mean scores at baseline and endpoint for all measures were: Clinician-Administered PTSD Scale - 82.7 (± 23.1) and 51.4 (± 31.4) (F = 11.247, p = 0.001); Beck Anxiety Inventory - 31.7 (± 13.4) and 25.4 (± 18.2) (F = 8.931, p = 0.011); Social Adjustment Scale - 2.4 (± 0.45) and 2.27 (± 0.57) (F = 8.633, p = 0.012); Medical Outcome Study Short Form 36 - 76.6 (± 14.11) and 94.01 (± 25.06) (F = 10.127 p = 0.007); and Beck Depression Inventory - 26.06 (± 11.6) and 21.35 (± 12.6) (F = 1.580, p = 0.042). In all measurements, the differences were statistically significant. CONCLUSIONS: Patients achieved a good response to treatment with aripiprazole, but placebo-controlled studies are needed for more accurate results.
publishDate 2008
dc.date.none.fl_str_mv 2008-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462008000400011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462008000400011
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1516-44462008000400011
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Psiquiatria
publisher.none.fl_str_mv Associação Brasileira de Psiquiatria
dc.source.none.fl_str_mv Brazilian Journal of Psychiatry v.30 n.4 2008
reponame:Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
instname:Associação Brasileira de Psiquiatria (ABP)
instacron:ABP
instname_str Associação Brasileira de Psiquiatria (ABP)
instacron_str ABP
institution ABP
reponame_str Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
collection Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
repository.name.fl_str_mv Brazilian Journal of Psychiatry (São Paulo. 1999. Online) - Associação Brasileira de Psiquiatria (ABP)
repository.mail.fl_str_mv ||rbp@abpbrasil.org.br
_version_ 1754212554267164672